This was a 20-week, open-label, uncontrolled clinical investigation of the long-acting calcium antagonist amlodipine in 33 male or female patients with essential hypertension and left ventricular hypertrophy (LVH). A once-daily dose (5–10 mg/day) of amlodipine provided a consistent antihypertensive effect, reducing the sitting diastolic (–13.8% change) and systolic (–13.0% change) blood pressures by clinically meaningful and statistically significant (p = 0.0001, n = 33) amounts. Amlodipine had no effect on heart rate. A significant regression in LVH was seen (left ventricular mass index reduced from 169.0 [SD 30.7] g/m2 to 140.6 [SD 19.6] g/m2, p < 0.01, n = 12). There was also a significant reduction in total peripheral resistance and improvement in left ventricular diastolic filling (E/A ratio increased from 0.86 pre-treatment to 1.03 post-treatment, p = 0.038, n = 12). These results are consistent with other studies in showing that a relatively short treatment regimen with amlodipine is associated with a significant reduction in left ventricular mass index.

Keywords:
Amlodipine, Left ventricular hypertrophy, Essential hypertension
1.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–1566.
2.
Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, Castelli WP: Left ventricular mass and risk of stroke in an elderly cohort: The Framingham Heart Study. JAMA 1994;272:33–36.
3.
Liao Y, Cooper RS, Mensah GA, MeGee DL: Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995;92:805–810.
4.
Mayet J, Shahi M, Hughes AD, Stanton AV, Poulter NR, Sever PS, Foale RA, Thom SA: Left ventricular structure and ventricular function in previously untreated hypertensive patients: The importance of blood pressure, the nocturnal pressure dip and heart rate. J Cardiovasc Risk 1995;2:255–261.
5.
Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27:341–348.
6.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450–458.
7.
Liebson PR, Savage DD: Electrocardiography in hypertension: A review: I. Left ventricular wall mass, standardization and ventricular function. Echocardiography 1986;3:181–218.
8.
Byrd BF III, Collins W, Hartness WO, Kronenberg MW: Superior reproducibility of serial left ventricular mass measurements by two-dimensional vs M-mode echocardiography. J Am Coll Cardiol 1988;11:146A (Abstract).
9.
Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992;117:831–836.
10.
Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies. Am J Hypertens 1992;5:95–110.
11.
Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, Stamler J: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91:698–706.
12.
Dahlöf B: Regression of cardiovascular structural changes – a preventive strategy. Clin Exp Hypertension 1990;A12(suppl):877–896.
13.
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345–352.
14.
Pfeffer MA, Pfeffer JM: Reversing cardiac hypertrophy in hypertension (editorial). N Engl J Med 1990;322:1388–1390.
15.
MacMahon SW, Wilcken DEL, MacDonald GJ: The effect of weight reduction on left ventricular mass: A randomized trial in young overweight patients. N Engl J Med 1986;314:334–339.
16.
Ferrara LA, de Simone G, Pasanisi F, Mancini M, Mancini M: Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 1984;6:755–759.
17.
Ruskoaho H: Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats. Med Biol 1984;62:263–276.
18.
Burges RA, Dodd MG: Amlodipine. Cardiovasc Drug Rev 1990;8:25–44.
19.
Picca M, Pelosi GC: Effects of enalapril and amlodipine on left ventricular hypertrophy and function in hypertension. Eur Heart J 1992;13(suppl):P1056 (Abstract).
20.
Agabiti-Rosei E, Muiesan ML, Rizzoni D, Zulli R, Calebich S, Castellano M, Cavaliere G, Nordio G, Pasini F, Zuccato F: Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol 1994;24(suppl A):S37–S43.
21.
Leenen FHH, Fourney A: Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines and left ventricular mass. Am J Cardiol 1996;78:203–207.
22.
Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in men: Anatomic validation of the method. Circulation 1977;55:613–618.
23.
Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987;59:956–960.
24.
Devereux RB: Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997;95:1983–1985.
25.
Schulte KL, Meyer-Sabellek W, Liederwald K, van Gemmeren D, Lenz T, Gotzen R: Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine. Am J Cardiol 1992;70:468–473.
26.
Burris JF, Allenby KS, Mroczek WJ: The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 1994;73:39A–43A.
27.
Mehmel HC, Gorne RC: Monotherapy of mild to moderate hypertension. Double blind comparative study: Amlodipine versus enalapril. Fortschr Med 1993;111:447–450.
28.
Perticone F, Pugliese F, Ceravola R, Mattioli PL: Amlodipine versus ramipril in the treatment of mild to moderate hypertension: Evaluation by 24-hour ambulatory blood pressure monitoring. Cardiology 1994;85:36–46.
29.
Ram CV, Ames RP, Applegate WB, Burris JF, Davidov ME, Mroczek WJ: Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Clin Cardiol 1994;17:251–256.
30.
Lorimer AR, Anderson JA, Laher MS, Davies J, Lazarus JH, Taylor SH, Sanghera S: Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to moderate hypertension. J Hum Hypertens 1994;8:65–68.
31.
Hoegholm A, Wiinberg N, Rasmussen E, Nielsen PE: Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group. J Hum Hypertens 1995;9(suppl 1):S25–S28.
32.
Sauerby-Wulkopf N, Anlauf M: Amlodipine in long-term treatment of mild and moderate hypertension: A multicentre study. Fortschr Med 1995;113:38–62.
33.
Meredith PA, Elliott HL: Therapeutic coverage: Reducing the risks of partial compliance. Br J Clin Pract Symp Suppl 1994;73:13–17.
34.
Rose M, McMahon FG: Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151–155.
35.
Mroczek WJ, Burris JF, Allenby KS: A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12(suppl 7):S79–S84.
36.
Heber ME, Brigden G, Al-Khawaja I, Raftery EB: 24-hour blood pressure control with the once daily calcium antagonist, amlodipine. Br J Clin Pharmacol 1989;27:359–365.
37.
Lacourciere Y, Poirier L, Provencher P: Comparison of the effects of amlodipine and captopril on clinic and ambulatory blood pressure. J Hum Hypertens 1992;6(suppl 1):S25–S28.
38.
Malacco E, Fogari R, Tettarnarti F, Magenta M: Twenty-four-hour blood pressure control using once daily treatment with a calcium antagonist or an angiotensin converting enzyme inhibitor. J Hypertens Suppl 1991;9:S372–S337.
39.
Coca A, Picado MJ, De la Sierra A, Aguilera MT, Sanchez M, Lluch MM, Urbano-Marquez A: Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension. J Cardiovasc Pharmacol 1993;22:513–518.
40.
Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507–1513.
41.
Wollam GL, Hall WD, Porter VD, Douglas MB, Unger DJ, Blumstein BA, Cotsonis GA, Knudtson ML, Felner JM, Schlant RC: Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983;75(suppl 3A):100–110.
42.
Leenen FHH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A: Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 1987;82:969–978.
43.
Bielen EC, Fagard RH, Lijnen PJ, Tjandra-Maga TB, Verbesselt R, Amery AK: Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol 1992;69:1200–1206.
44.
Hanrath P, Mathey DG, Siegert R, Bleifield W: Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: An echocardiographic study. Am J Cardiol 1980;45:15–23.
45.
Yamamoto K, Redfield MM, Nishimura RA: Analysis of left ventricular diastolic function. Heart 1996;75(suppl 2):27–35.
46.
Nishimura RA, Tajik J: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s rosetta stone. J Am Coll Cardiol 1997;30:8–18.
47.
Giannuzzi P, Imparato A, Temporelli PL, de Vito F, Silva PL, Scapellato F, Giordano A: Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1994;23:1630–1637.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.